

Appl. No. : unknown  
Filed : herewith

## REMARKS

Applicants wish to thank Examiner Allen for the courtesy extended to their representative, Nancy W. Vensko, on January 22, 2001, in U.S. Pat. Appl. No. 08/428,242, filed Sept 18, 1995. The Interview Summary Form PTOL-413 summarizes the discussions held at the personal interview (attached). The present remarks address the substance of the Examiner Interview.

### I. Disposition Of Claims

Claims 1-16 are presented for examination.

### II. Human and Rat Serotonin Receptor Protein St-B17

The invention relates to isolated human serotonin receptor protein St-B17 (Claim 1) and isolated rat serotonin receptor protein St-B17 (Claim 9), and related constructs, polynucleotides, cell lines, and products-by-process.

### III. No New Sequence Listing

While disagreeing with the position by the PTO that depositing a biological material after the priority date introduces new matter into this application, to advance prosecution Applicant has refrained from introducing a biological deposit or deposit information herein. Neither has Applicant introduced a new sequence listing in paper form or computer readable form (CRF) into this application to conform to any biological deposit. Rather, Applicant has copied the *original* sequence listing in paper form and computer readable form (CRF) that was filed in response to the Notice to Comply in the parent application to which this continuation application relates back.

### IV. Corrected Rat and Human Sequences

Under 37 CFR 1.56, Applicant wishes to meet his duty to disclose by making of record errors in the sequence listing.

Beginning with rat, SEQ ID NO:7 is the DNA sequence and SEQ ID NO:8 is the amino acid sequence encoding rat serotonin receptor protein St-B17, as originally filed on October 26, 1992. The inventors and their colleagues subsequently published this

Appl. No. : unknown  
Filed : herewith

sequence as Monsma et al., Molecular Pharmacology 43:320 (March 1993) (attached). Other colleagues published this sequence as Ruat et al., Biochem Biophys Res Comm 193:268 (May 1993) (attached). Later, the inventors and their colleagues published the corrected sequence in Kohen et al., J. of Neurochemistry 66:47 (1996) (attached), which points out the particular changes in both the DNA and amino acid sequences.

Turning to human, SEQ ID NO:12 is the DNA sequence and SEQ ID NO:13 is the amino acid sequence encoding human serotonin receptor protein St-B17, as originally filed on October 26, 1993. The inventors and colleagues subsequently published the corrected sequence in Kohen et al., supra. Exhibit 1 (attached) points out the particular changes in the DNA sequence, and Exhibit 2 (attached) points out the particular changes in the amino acid sequence.

V. Claiming by Crucial Third and Sixth Transmembrane Domains

The claims are directed to isolated human serotonin receptor protein St-B17 (Claim 1) and isolated rat serotonin receptor protein St-B17 (Claim 9), and related constructs, polynucleotides, cell lines, and products-by-process, where the serotonin receptor protein St-B17 is defined by reference to crucial transmembrane domains III and VI. Trends in Pharmacology 13:160 (April 1992) (attached) shows that, at the time of the Oct 26, 1992 priority date of the present application, most serotonin receptors were known to be G protein-linked receptors having a putative seven transmembrane domain structure. Here is Trends in Pharmacology Figure 3 showing putative transmembrane domains numbered I to VII for previously known serotonin receptors:

| I   |  | II  |  |
|---|--|-----|--|
| 5-HT <sub>1B</sub> (mouse) (48)             | -VALLALITLATTLSNAFVIATVYRTRKLHTPANYLIASLAVTDLLVSIIVMPISITMYT     |     |  |
| 5-HT <sub>1D<sub>1</sub></sub> (dog) (41)   | -ALLLSIITMATALSNAFVLTITFLTRKLHTPANYLIGSLAMTDLLVSIIVMPISIA        |     |  |
| 5-HT <sub>1D<sub>2</sub></sub> (human) (41) | -AVVLSVITLAVLSNAFVLTITILLTRKLHTPANYLIGSLATTDLLVSIIVMPISIA        |     |  |
| 5-HT <sub>1A</sub> (rat) (39)               | -SLLGLTILFCAVLGNACVVAIALERSLQNVANYLIGSLAVTDLMVSVLVLPMAALYQ       |     |  |
| 5-HT <sub>dr2A</sub> (229)                  | -SVLLGLMILVTIIGNVFVIAAIIERNLQNVANYLVASLAVADLFVACLVMPLGAVY        |     |  |
| 5-HT <sub>dr2B</sub> (80)                   | -AVVLGLMILVTIIGNVFVIAAIIERNLQNVANYLVASLAVADLFVACLVMPLGAVY        |     |  |
| 5-HT <sub>dr1</sub> (165)                   | -SIVLLVILGTVVGNVLCIACVMRKLFRPCNYLLVSLALSDLCVALLVMPMALLYE         |     |  |
| 5-HT <sub>1C</sub> (rat) (57)               | -ALSIVVITIMTIGGNILVIMAVSMEKKLHNATNYFLMSLAIDMLVGLLVMPLSLL         |     |  |
| 5-HT <sub>2</sub> (rat) (77)                | -ALLTTVVIILTIAGNIVLIMAVSLEKKLQVATNYFLMSLAIDMLLVGLVMPVCM          |     |  |
| III   |  |     |  |
| 5-HT <sub>1B</sub> (mouse)                  | G-RWTLGQVVCDFWLSSDITCCTASIMHLCVIALDRYWAITDAVEYSAKRTPKFAA         |     |  |
| 5-HT <sub>1D<sub>1</sub></sub> (dog)        | R-TWTFGQILCDIWLSSDITCCTASIMHLCVIALDRYWAITDALEYSKERTAGFAA         |     |  |
| 5-HT <sub>1D<sub>2</sub></sub> (human)      | H-TWTFGQILCDIWLSSDITCCTASIMHLCVIALDRYWAITDALEYSKERTAGFAA         |     |  |
| 5-HT <sub>1A</sub> (rat)                    | N-KWTLGQVVCDFWLSSDITCCTASIMHLCVIALDRYWAITDALEYSKERTAGFAA         |     |  |
| 5-HT <sub>dr2A</sub>                        | Q-GWILGPHLCDIWTSCDVLCCCTASIMHLCVIALDRYWAITDALEYSKERTAGFAA        |     |  |
| 5-HT <sub>dr2B</sub>                        | N-GWILGPHLCDIWTSCDVLCCCTASIMHLCVIALDRYWAITDALEYSKERTAGFAA        |     |  |
| 5-HT <sub>dr1</sub>                         | E-KWTFGQILCDIWTSCDVLCCCTASIMHLCVIALDRYWAITDALEYSKERTAGFAA        |     |  |
| 5-HT <sub>1C</sub> (rat)                    | EYVWPLPFPYLCFVWISLQVLESTASIMHLCVIALDRYWAITDALEYSKERTAGFAA        |     |  |
| 5-HT <sub>2</sub> (rat)                     | GYRWPLPSPKLCVIAWIYLDVLESTASIMHLCVIALDRYWAITDALEYSKERTAGFAA       |     |  |
| IV  |  | V   |  |
| 5-HT <sub>1B</sub> (mouse)                  | LVWVFSISISIP-PFF-WRQA--AQRMSDQVNTLISYTIYSTGAFYIPGVLLIIL          |     |  |
| 5-HT <sub>1D<sub>1</sub></sub> (dog)        | TVWVFSISISIP-PFF-WRQA--AQRMSDQVNTLISYTIYSTGAFYIPGVLLIIL          |     |  |
| 5-HT <sub>1D<sub>2</sub></sub> (human)      | IVWVFSISISIP-PFF-WRQA--AQRMSDQVNTLISYTIYSTGAFYIPGVLLIIL          |     |  |
| 5-HT <sub>1A</sub> (rat)                    | LTWVFSISISIP-PFF-WRQA--AQRMSDQVNTLISYTIYSTGAFYIPGVLLIIL          |     |  |
| 5-HT <sub>dr2A</sub>                        | QVWVFSISISIP-PFF-WRQA--AQRMSDQVNTLISYTIYSTGAFYIPGVLLIIL          |     |  |
| 5-HT <sub>dr2B</sub>                        | QVWVFSISISIP-PFF-WRQA--AQRMSDQVNTLISYTIYSTGAFYIPGVLLIIL          |     |  |
| 5-HT <sub>dr1</sub>                         | IVWVFSISISIP-PFF-WRQA--AQRMSDQVNTLISYTIYSTGAFYIPGVLLIIL          |     |  |
| 5-HT <sub>1C</sub> (rat)                    | IVWVFSISISIP-PFF-WRQA--AQRMSDQVNTLISYTIYSTGAFYIPGVLLIIL          |     |  |
| 5-HT <sub>2</sub> (rat)                     | AVWTISVCSISIP-PFF-WRQA--AQRMSDQVNTLISYTIYSTGAFYIPGVLLIIL         |     |  |
|   |  | VI  |  |
| 5-HT <sub>1B</sub> (mouse)                  | YG-FIYFAAFNRILNP - (57) - EKKILAAKREFAATLGIILGAFIVCWLPFFVLS      |     |  |
| 5-HT <sub>1D<sub>1</sub></sub> (dog)        | YG-FIYFAAFNRILNP - (55) - EKKILAAKREFAATLGIILGAFIVCWLPFFVLS      |     |  |
| 5-HT <sub>1D<sub>2</sub></sub> (human)      | YG-FIYFAAFNRILNP - (55) - EKKILAAKREFAATLGIILGAFIVCWLPFFVLS      |     |  |
| 5-HT <sub>1A</sub> (rat)                    | YG-FIYFAAFNRILNP - (57) - EKKILAAKREFAATLGIILGAFIVCWLPFFVLS      |     |  |
| 5-HT <sub>dr2A</sub>                        | YW-FIYFAAFNRILNP - (316) - EKKILAAKREFAATLGIILGAFIVCWLPFFVLS     |     |  |
| 5-HT <sub>dr2B</sub>                        | YW-FIYFAAFNRILNP - (235) - EKKILAAKREFAATLGIILGAFIVCWLPFFVLS     |     |  |
| 5-HT <sub>dr1</sub>                         | YY-QIFFAARIVLHE - (83) - EKKILAAKREFAATLGIILGAFIVCWLPFFVLS       |     |  |
| 5-HT <sub>1C</sub> (rat)                    | YFLTIYVLEFQILMLP - (50) - EKKILAAKREFAATLGIILGAFIVCWLPFFVLS      |     |  |
| 5-HT <sub>2</sub> (rat)                     | YFLTIYVLEFQILMLP - (41) - EKKILAAKREFAATLGIILGAFIVCWLPFFVLS      |     |  |
|   |  | VII |  |
| 5-HT <sub>1B</sub> (mouse)                  | LVLFIICDSCW--LHPALFIFTWLGYNLSLNP IYTVFNHEFRQAFQKIVFFKAS          |     |  |
| 5-HT <sub>1D<sub>1</sub></sub> (dog)        | LVLFIICDSCW--LHPALFIFTWLGYNLSLNP IYTVFNHEFRQAFQKIVFFKAS          |     |  |
| 5-HT <sub>1D<sub>2</sub></sub> (human)      | LVLFIICDSCW--LHPALFIFTWLGYNLSLNP IYTVFNHEFRQAFQKIVFFKAS          |     |  |
| 5-HT <sub>1A</sub> (rat)                    | LVLFIICDSCW--LHPALFIFTWLGYNLSLNP IYTVFNHEFRQAFQKIVFFKAS          |     |  |
| 5-HT <sub>dr2A</sub>                        | LTMFLCAA-CQ--ISDVANLFLWLGYFNSTLNPVIYTFSPFQRQAFKILFGGRFP - (8)    |     |  |
| 5-HT <sub>dr2B</sub>                        | LTMFLCAA-CQ--ISDVANLFLWLGYFNSTLNPVIYTFSPFQRQAFKILFGGRFP - (8)    |     |  |
| 5-HT <sub>dr1</sub>                         | LIRPF--HTMH--VPASLSLFLWLGYANSLLNP IYATLNRDFRQAFQKIVFFKAS - (36)  |     |  |
| 5-HT <sub>1C</sub> (rat)                    | ILSVLCGHACNQKLMEKLLNVFVWIGYVCSGINPLVYTLFNKIYRAFSKYLFQYKFP - (69) |     |  |
| 5-HT <sub>2</sub> (rat)                     | IMAVICRESCNENVIGALLNVFVWIGYVCSGINPLVYTLFNKIYRAFSKYLFQYKFP - (70) |     |  |

Fig. 3. Aligned amino acid sequence homologies of 5-HT receptors. Tint shows positions where more than 6 out of the 9 sequences are identical. Putative transmembrane domains are numbered I to VII. Numbers in parentheses correspond to amino acids not represented. Arrow after domain VII indicates amino acid whose charge varies depending on how the receptor is coupled with second messenger systems. Data from Refs 6, 9-11, 19, 20.

The patent specification (at Example 1, page 8, line 30 et seq.) shows that, beginning with sequences that were derived from the third and sixth transmembrane domains of previously known G protein-linked receptors, the present inventors cloned and expressed a rat cDNA that encoded a novel serotonin receptor called St-B17 with high affinity for tricyclic psychotropic drugs. The pat spec (at page 12, line 15 et seq.) additionally shows that hydropathy analysis of the deduced amino acid sequence indicated seven hydrophobic regions predicted to represent putative transmembrane domains I-VII. The pat spec (at page 12, line 22 et seq.) further shows that when compared with previously known G protein-coupled receptors, the transmembrane domains of St-B17 exhibited homologies of 41%, 40%, 39%, 38%, 37%, and 36% to 5-HT<sub>2</sub>, 5-HT<sub>1D</sub>, 5-HT<sub>1C</sub>, 5-HT<sub>1B</sub>, 5-HT<sub>1A</sub>, and 5-HT<sub>1E</sub> serotonin receptors, respectively.

As indicated in Kohen et al., supra, a frame shift error had occurred in the rat clone, but the error occurred in the long carboxyl terminus tail, well past the seven transmembrane domains. As shown in Exhibits 1 and 2, a frame shift error had occurred in the human clone, too, but the error occurred in the long carboxyl terminus tail, well past the seven transmembrane domains, also. Monsma et al., supra, Figure 1, and Ruat et al., supra, Figure 1 for rat, and Kohen et al., supra, Figures 1 and 2 for human, illustrate the seven transmembrane domains. Trends in Pharmacology, supra, shows that, at the time of the Oct 26, 1992 priority date of the present application, transmembrane domain III and VI were known to contain conserved amino acids that were presumed to interact with the ligand, serotonin. Consistent with this information and the pat spec (at page 8, lines 31-34), the invention is claimed by reference to crucial transmembrane domains III and VI, the sequence from which was derived the degenerate primers to clone the rat cDNA encoding the novel serotonin receptor called St-B17.

Appl. No. : unknown  
Filed : herewith

VI. Monsma et al., Ruat et al., and Kohen et al.

As indicated above, the inventors cloned and expressed a novel serotonin receptor. There is no identity with other serotonin receptors as shown by the fact that the transmembrane domains of St-B17 exhibited homologies of 41%, 40%, 39%, 38%, 37%, and 36% to 5-HT<sub>2</sub>, 5-HT<sub>1D</sub>, 5-HT<sub>1C</sub>, 5-HT<sub>1B</sub>, 5-HT<sub>1A</sub>, and 5-HT<sub>1E</sub> serotonin receptors, respectively (see *supra*). Additionally, the above dates show that Monsma et al. and Ruat et al., describing the cloning of the rat St-B17 serotonin receptor, occurred at a time *after* the Oct 26, 1992 priority date of the present application in which the cloning of the rat St-B17 serotonin receptor is disclosed. Furthermore, the above dates show that Kohen et al., describing the cloning of the human St-B17 serotonin receptor, occurred at a time *after* the Oct 26, 1993 priority date of the present application in which the cloning of the human St-B17 serotonin receptor is disclosed. Because these scientific publications are not *prior* art, they cannot bar patentability of the present invention.

#### Conclusion

In view of the foregoing, Applicant respectfully requests that the present amendment be entered prior to examination of this application. It is respectfully submitted that the present application is in condition for allowance. Should any points remain that can be resolved by telephone, the Examiner is invited to contact the undersigned at the below-given telephone number.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 4/10/01

By: Nancy W. Vensko  
Nancy W. Vensko  
Registration No. 36,298  
Attorney of Record  
620 Newport Center Drive, 16th Floor  
Newport Beach, CA 92660  
805 547-5585



^320 ^330 ^340 ^350 ^360 ^370 ^380 ^390  
v740 v750 v760 v770 v780 v790 v800 v810  
GTACGGCGCTGGGTGCTGGCGCGGGCCTCTGCCTGCTCTGGACCGCCTTCGACGTGATGTGCTGCAGCGCCTCCATCC  
GTACGGCGCTGGGTGCTGGCGCGGGCCTCTGCCTGCTCTGGACCGCCTTCGACGTGATGTGCTGCAGCGCCTCCATCC  
GTACGGCGCTGGGTGCTGGCGCGGGCCTCTGCCTGCTCTGGACCGCCTTCGACGTGATGTGCTGCAGCGCCTCCATCC  
^400 ^410 ^420 ^430 ^440 ^450 ^460 ^470  
v820 v830 v840 v850 v860 v870 v880 v890  
TCAACCTCTGCCTCATCAGCCTGGACCGCTACCTGCTCATCCTCTGCGCGTGGCTACAAAGCTGGCATGACGCCCCCTG  
TCAACCTCTGCCTCATCAGCCTGGACCGCTACCTGCTCATCCTCTGCGCGTGGCTACAAAGCTGGCATGACGCCCCCTG  
TCAACCTCTGCCTCATCAGCCTGGACCGCTACCTGCTCATCCTCTGCGCGTGGCTACAAAGCTGGCATGACGCCCCCTG  
^480 ^490 ^500 ^510 ^520 ^530 ^540 ^550  
v900 v910 v920 v930 v940 v950 v960 v970  
CGTGCCCTGGCCCTAGTCCTGGCGGCTGGAGCCTGCGCGCTCTCGCCTCCTTCCCTGCCCTGCTGCTGGCTGGCACGA  
CGTGCCCTGGCCCTAGTCCTGGCG CTGGAGCCTGCGCGCTCTCGCCTCCTTCCCTGCCCTGCTGCTGGCTGGCACGA  
CGTGCCCTGGCCCTAGTCCTGGCGGCTGGAGCCTGCGCGCTCTCGCCTCCTTCCCTGCCCTGCTGCTGGCTGGCACGA  
^560 ^570 ^580 ^590 ^600 ^610 ^620 ^630  
v980 v990 v1000 v1010 v1020 v1030 v1040 v1050  
GCTGGCCACGCACGGCCACCCGTCCTCCCTGGCCAGTGCCGCTGCTGGCCAGCCTGCTTGTCTTGTGGCTGGGGCC  
GCTGGCCACGCACGGCCACCCGTCCTCCCTGGCCAGTGCCGCTGCTGGCCAGCCTGCTTGTCTTGTGGCTGGGGCC  
GCTGGCCACGCACGGCCACCCGTCCTCCCTGGCCAGTGCCGCTGCTGGCCAGCCTGCTTGTCTTGTGGCTGGGGCC  
^640 ^650 ^660 ^670 ^680 ^690 ^700 ^710  
v1060 v1070 v1080 v1090 v1100 v1110 v1120 v1130  
TCACCTTCTTCTGCTGGGTGCCATATGCTTCACTACTGCAGGATCCTGCTAGCTGCCCGAAGCAGGCCGTGCAG  
TCACCTTCTTCTGCTGGGTGCCATATGCTTCACTACTGCAGGATCCTGCTAGCTGCCCGAAGCAGGCCGTGCAG  
TCACCTTCTTCTGCTGGGTGCCATATGCTTCACTACTGCAGGATCCTGCTAGCTGCCCGAAGCAGGCCGTGCAG  
^720 ^730 ^740 ^750 ^760 ^770 ^780 ^790  
v1140 v1150 v1160 v1170 v1180 v1190 v1200  
GTGGCCTCCCTCACCACCGCATGGCCAGTCAGGCCCTCGGAGACGCTGCAGGTGCCAGGCCACCCACGCC-CAGGGGTGG  
GTGGCCTCCCTCACCACCGCATGGCCAGTCAGGCCCTCGGAGACGCTGCAGGT CCCAGGA CCCA GC CAGGGGTGG  
GTGGCCTCCCTCACCACCGCATGGCCAGTCAGGCCCTCGGAGACGCTGCAGGTACCCAGGAGCCCA-GCGGCAGGGGTGG

^800 ^810 ^820 ^830 ^840 ^850 ^860 ^870  
 v1210 v1220 v1230 v1240 v1250 v1260 v1270 v1280  
 AGTCTGCTGACAGCAGGCGTCTAGCCACGAAGCA-CAGCAGGAAGGCCCTGAAGGCCAGCCTGACGCTGGGCATCCTGCT  
 AGTCTGCTGACAGCAGGCGTCTAGC ACGAAG A CAGCAGGAAGG CCTGAAGGCCAGC TGACGCTGGGCATCCTGCT  
 AGTCTGCTGACAGCAGGCGTCTAGCAACGAAG-AGCAGCAGGAAGGCCCTGAAGGCCAGCATGACGCTGGGCATCCTGCT  
 ^880 ^890 ^900 ^910 ^920 ^930 ^940 ^950  
 v1290 v1300 v1310 v1320 v1330 v1340 v1350 v1360  
 GGCATGTTCTTTGTGACCTGGTTGCCCTTCTTTGTGGCCAACATAGTCCAGGCCGTGTGCGACTGCATCTCCCCAGGCC  
 GGCATGTTCTTTGTGACCTGGTTGCCCTTCTTTGTGGCCAACATAGTCCAGGCCGTGTGCGACTGCATCTCCCCAGGCC  
 GGCATGTTCTTTGTGACCTGGTTGCCCTTCTTTGTGGCCAACATAGTCCAGGCCGTGTGCGACTGCATCTCCCCAGGCC  
 ^960 ^970 ^980 ^990 ^1000 ^1010 ^1020 ^1030  
 v1370 v1380 v1390 v1400 v1410 v1420 v1430 v1440  
 TCTTCGATGTCCCTCACATGGCTGGGTTACTGTAAACAGCACCATGAACCCCATCATCTACCCACTCTTTCATGCGGACTTC  
 TCTTCGATGTCCCTCACATGGCTGGGTTACTGTAAACAGCACCATGAACCCCATCATCTACCCACTCTTTCATGCGGACTTC  
 TCTTCGATGTCCCTCACATGGCTGGGTTACTGTAAACAGCACCATGAACCCCATCATCTACCCACTCTTTCATGCGGACTTC  
 ^1040 ^1050 ^1060 ^1070 ^1080 ^1090 ^1100 ^1110  
 v1450 v1460 v1470 v1480 v1490 v1500 v1510 v1520  
 AAGCGGCGCTGGGCAGGTTCTTGCCATGTCCACGCTGTCCCGGGAGCGCCAGGCCAGCCTGGCCTCGCCATCACTGCG  
 AAGCGGCGCTGGGCAGGTTCTTGCCATGTCCACGCTGTCCCGGGAGC CCAGGCCAGCCTGGCCTCGCCATCACTGCG  
 AAGCGGCGCTGGGCAGGTTCTTGCCATGTCCACGCTGTCCCGGGAGC-CCAGGCCAGCCTGGCCTCGCCATCACTGCG  
 ^1120 ^1130 ^1140 ^1150 ^1160 ^1170 ^1180 ^1190  
 v1530 v1540 v1550 v1560 v1570 v1580 v1590 v1600  
 CACCTCTCACAGCGCCCCCGCGCCCTTAGCCTACAGCAGGTGCTGCCGTGCCCTGCCCGCCGACTCAGATTTCGG  
 CACCTCTCACAGCGCCCCCGCGCCCTTAGCCTACAGCAGGTGCTGCCGTGCCCTGCCCGCCGACTCAGATTTCGG  
 CACCTCTCACAGCGCCCCCGCGCCCTTAGCCTACAGCAGGTGCTGCCGTGCCCTGCCCGCCGACTCAGATTTCGG  
 ^1200 ^1210 ^1220 ^1230 ^1240 ^1250 ^1260 ^1270  
 v1610 v1620 v1630 v1640 v1650 v1660 v1670 v1680  
 ACTCAGACGCAGGCTCAGCGGCTCCTCGGCTCAGGCCAGCTGCTGCTTCTTGCGAGGCCACCCAGGAC  
 ACTCAGACGCAGGCTCAGCGGCTCCTCGGCTGCGGCTCAGGCCAGCTGCTGCTTCTTGCGAGGCCACCCAGGAC  
 ACTCAGACGCAGGCTCAGCGGCTCCTCGGCTCAGGCCAGCTGCTGCTTCTTGCGAGGCCACCCAGGAC



v1690 v1700 v1710 v1720 v1730 v1740 v1750 v1760  
CCCCGCTGCCACACGAGGCGCTGCCGCGCTCAATTCTTCAACATCG-ACCCCGGAGCCCGAGCTGCGGCCGCATC  
CCCCGCTGCCACACGAGGCGCTGCCGCGCTCAATTCTTCAACATCG ACCCCGGAGCCCGAGCTGCGGCCGCATC  
CCCCGCTGCCACACGAGGCGCTGCCGCGCTCAATTCTTCAACATCG\$ACCCCGGAGCCCGAGCTGCGGCCGCATC  
^1360 ^1370 ^1380 ^1390 ^1400 ^1410 ^1420 ^1430  
  
v1770 v1780 v1790 v1800 v1810 v1820 v1830 v1840  
CACTTGGCATCCCCACGAACTGACCCGGGCTTGGGGCTGGCCAAATGGGAGCTGGATTGAGCAGAAACCCAGACCCCTGAGT  
CACTTGGCATCCCCACGAACTGACCC GGCTTGGGGCTGGCCAAATGGGAGCTGGATTGAGCAGAAACCCAGACCCCTGAGT  
CACTTGGCATCCCCACGAACTGACCC-GGCTTGGGGCTGGCCAAATGGGAGCTGGATTGAGCAGAAACCCAGACCCCTGAGT  
^1440 ^1450 ^1460 ^1470 ^1480 ^1490 ^1500 ^1510  
  
v1850 v1860 v1870 v1880 v1890 v1900 v1910 v1920  
CCTTGGGCCAGCTCTTGGCTAAGACACGAGGCTGCAAGTCTCCTAGAAGCCCTCTGAGCTCCAGAGGGTGCG-CAGAG  
CCTTGGGCCAGCTCTTGGCTAAGACACGAGGCTGCAAGTCTCCTAGAAGCCCTCTGAGCTCCAGAGGGTGCG CAGAG  
CCTTGGGCCAGCTCTTGGCTAAGACACGAGGCTGCAAGTCTCCTAGAAGCCCTCTGAGCTCCAGAGGGTGCGGCAGAG  
^1520 ^1530 ^1540 ^1550 ^1560 ^1570 ^1580 ^1590  
  
v1930 v1940 v1950 v1960 v1970 v1980  
CTGACCCCTGCTGCCATCTCCAGGCCCTTACCTGCAGGGATCATAGCTGACTCAGA  
CTGACCCCTGCTGCCATCTCCAGGCCCTTACCTGCAGGGATCATAGCTGACT AGA  
CTGACCCCTGCTGCCATCTCCAGGCCCTTACCTGCAGGGATCATAGCTGACT-AGA  
^1600 ^1610 ^1620 ^1630 ^1640

### Lipman-Pearson Protein Alignment

Seq1(1>440) pep h5-HT6 GSDB S40337 Flatfile PEP  
Seq2(1>439) Seq ID' 13 - h 5-HT6 from application

(1>440)  
(1>439)

|                  |            |            |                  |
|------------------|------------|------------|------------------|
| Similarity Index | Gap Number | Gap Length | Consensus Length |
| 79.6             | 5          | 5          | 442              |

[illegible]